Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2016

Open Access 01-12-2016 | Original article

Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study

Authors: Huang-Tz Ou, Kai-Cheng Chang, Chung-Yi Li, Jin-Shang Wu

Published in: Cardiovascular Diabetology | Issue 1/2016

Login to get access

Abstract

Background

Several antidiabetic drugs (i.e., sulfonylureas; SU, rosiglitazone) have been reported to be associated with increased risks of cardiovascular diseases (CVD) in patients with type 2 diabetes mellitus (T2DM). Dipeptidyl peptidase-4 inhibitors (DPP4i) are newly available antidiabetic drugs. Most studies only compared DPP4i with a placebo or SU, or targeted a specific CVD event of interest (i.e., heart failure; HF). Comparative research of CVD risks of DPP4i with other antidiabetic drugs (i.e., metformin, thiazolidinediones, meglitinides, acarbose, and insulin) remains scarce. This study was aimed to assess comparative risks of CVD, including ischemic stroke, myocardial infarction (MI) and HF, and hypoglycemia of DPP4i with other antidiabetic drugs.

Methods

We utilized Taiwan’s National Health Insurance Research Database. A total of 123,050 T2DM patients newly prescribed oral antidiabetic treatments were identified in 2009–2010 and followed until 2013. Outcome endpoints included a composite of CVD events: hospitalizations for ischemic stroke, MI and HF, and hypoglycemia. Time-varying Cox proportional hazards regression was applied to assess the time to event hazards of various antidiabetic drugs, adjusted for patients’ demographics, comorbidity, diabetic complications, and co-medications. Additional analyses were performed for the patients with and without CVD history, respectively.

Results

DPP4i users had significantly lower CVD risks as compared to that of non-DPP4i users (adjusted hazard ratio [aHR]: 0.83, 95 % confidence interval [CI]: 0.76–0.91). Compared to DPP4i users, meglitinides (aHR 1.3, 95 % CI 1.20–1.43) and insulin users (aHR 3.73, 95 % CI 3.35, 4.14) had significantly higher risks for composite CVD, as well as those for stroke, MI, HF, and hypoglycemia. Additionally, metformin users had significantly lower risks for composite CVD risk (aHR 0.87, 95 % CI 0.79–0.94), as well as those for MI, HF, and hypoglycemia, as compared to those of DPP4i users. Although there was a trend toward low CVD risks in pioglitazone users, the role of potential confounding by indication cannot be excluded.

Conclusions

DPP4i-treated T2DM patients had lower risks for CVD as compared to those for non-DPP4i users, except metformin users.
Appendix
Available only for authorised users
Literature
1.
Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971–1993. Diabetes Care. 1998;21(7):1138–45.CrossRefPubMed
2.
Jorgensen CH, Gislason GH, Andersson C, Ahlehoff O, Charlot M, Schramm TK, Vaag A, Abildstrom SZ, Torp-Pedersen C, Hansen PR. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention–a retrospective nationwide cohort study. Cardiovasc Diabetol. 2010;9:54.CrossRefPubMedPubMedCentral
3.
Margolis DJ, Hoffstad O, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf. 2008;17(8):753–9.CrossRefPubMedPubMedCentral
4.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–71.CrossRefPubMed
5.
Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011;342:d1309.CrossRefPubMedPubMedCentral
6.
Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ, Team RS. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125–35.CrossRefPubMed
7.
UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–65.CrossRef
8.
Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Group S-NTR: acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486–94.CrossRefPubMed
9.
Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Group S-NTR: acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359(9323):2072–7.CrossRefPubMed
10.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.CrossRefPubMed
11.
Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, Dugi KA, Woerle H-J. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475–83.CrossRefPubMed
12.
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.CrossRefPubMed
13.
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.CrossRefPubMed
14.
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42.CrossRefPubMed
15.
Mogensen U, Andersson C, Fosbøl E, Schramm T, Vaag A, Scheller NM, Torp-Pedersen C, Gislason G, Køber L. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus–a retrospective nationwide study. Diabetes Obes Metab. 2014;16(10):1001–8.CrossRefPubMed
16.
Kim SC, Glynn RJ, Liu J, Everett BM, Goldfine AB. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Acta Diabetol. 2014;51(6):1015–23.CrossRefPubMedPubMedCentral
17.
Morgan CL, Mukherjee J, Jenkins-Jones S, Holden S, Currie C. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab. 2014;16(10):977–83.CrossRefPubMed
18.
Chang YC, Chuang LM, Lin JW, Chen ST, Lai MS, Chang CH. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study. Diabet Med. 2015;32(11):1460–9.CrossRefPubMed
19.
Ou S-M, Shih C-J, Chao P-W, Chu H, Kuo S-C, Lee Y-J, Wang S-J, Yang C-Y, Lin C-C, Chen T-J. Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med. 2015.
20.
Fadini GP, Avogaro A, Degli Esposti L, Russo P, Saragoni S, Buda S, Rosano G, Pecorelli S, Pani L. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. Eur Heart J. 2015;36(36):2454–62.CrossRefPubMed
21.
Kannan S, Pantalone KM, Matsuda S, Wells BJ, Karafa M, Zimmerman RS. The risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: a large database study from Cleveland Clinic. J Diabetes. 2015.
22.
Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–51.CrossRefPubMed
23.
Young BA, Lin E, Von Korff M, Simon G, Ciechanowski P, Ludman EJ, Everson-Stewart S, Kinder L, Oliver M, Boyko EJ, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14(1):15–23.PubMedPubMedCentral
24.
Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18(11):721–6.PubMed
25.
Chen H-L, Hsiao F-Y. Risk of hospitalization and healthcare cost associated with Diabetes Complication Severity Index in Taiwan’s National Health Insurance Research Database. J Diabetes Complications. 2014;28(5):612–6.CrossRefPubMed
26.
Eurich D, Simpson S, Senthilselvan A, Asche C, Sandhu-Minhas J, McAlister F. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ. 2013;346:f2267.CrossRefPubMedPubMedCentral
27.
Chen D-Y, Wang S-H, Mao C-T, Tsai M-L, Lin Y-S, Su F-C, Chou C-C, Wen M-S, Wang C-C, Hsieh I-C. Sitagliptin After ischemic stroke in type 2 diabetic patients: a nationwide cohort study. Medicine 2015;94(28).
28.
Wang S-H, Chen D-Y, Lin Y-S, Mao C-T, Tsai M-L, Hsieh M-J, Chou C-C, Wen M-S, Wang C-C, Hsieh I-C. Cardiovascular outcomes of sitagliptin in type 2 diabetic patients with acute myocardial infarction, a population-based cohort study in Taiwan. PLoS ONE. 2015;10(6):e0131122.CrossRefPubMedPubMedCentral
29.
Muis M, Bots M, Grobbee D, Stolk R. Insulin treatment and cardiovascular disease; friend or foe? A point of view. Diabetic Med. 2005;22(2):118–26.CrossRefPubMed
30.
Huang Y, Abdelmoneim AS, Light P, Qiu W, Simpson SH. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. J Diabetes Complicat. 2015;29(2):196–202.CrossRefPubMed
31.
Chang S-H, Wu L-S, Chiou M-J, Liu J-R, Yu K-H, Kuo C-F, Wen M-S, Chen W-J, Yeh Y-H, See L-C. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014;13:123.CrossRefPubMedPubMedCentral
32.
Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11(5):506–15.CrossRefPubMed
33.
Lu C-J, Sun Y, Muo C-H, Chen R-C, Chen P-C, Hsu CY. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study. Cerebrovasc Diseases. 2013;36(2):145–51.CrossRef
34.
Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM. Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus. Pharmacoepidemiol Drug Saf. 2011;20(8):785–96.CrossRefPubMed
35.
Berthet S, Olivier P, Montastruc J-L, Lapeyre-Mestre M. Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database. BMC Pharmacol Toxicol. 2011;11(1):5.CrossRef
36.
Gallagher AM, Smeeth L, Seabroke S, Leufkens H, Van Staa TP. Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data. PLoS ONE. 2011;6(12):e28157.CrossRefPubMedPubMedCentral
37.
Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S. Thiazolidinedione use, fluid retention, and congestive heart failure a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108(23):2941–8.CrossRefPubMed
38.
Standl E, Theodorakis MJ, Erbach M, Schnell O, Tuomilehto J. On the potential of acarbose to reduce cardiovascular disease. Cardiovasc Diabetol. 2014;13:81.CrossRefPubMedPubMedCentral
39.
Heine R, Balkau B, Ceriello A, Del Prato S, Horton E, Taskinen MR. What does postprandial hyperglycaemia mean? Diabet Med. 2004;21(3):208–13.CrossRefPubMed
40.
Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010;12(4):288–98.CrossRefPubMed
41.
Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab. 2006;91(3):837–42.CrossRefPubMed
42.
Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol. 2010;9:12.CrossRefPubMedPubMedCentral
43.
Yu OHY, Yin H, Azoulay L. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death. Can J Diabetes. 2015;39(5):383–9.CrossRefPubMed
44.
Seong J-M, Choi N-K, Shin J-Y, Chang Y, Kim Y-J, Lee J, Kim J-Y, Park B-J. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study. PLoS ONE. 2015;10(5):e0124287.CrossRefPubMedPubMedCentral
45.
Onuma H, Inukai K, Watanabe M, Sumitani Y, Hosaka T, Ishida H. Effects of long-term monotherapy with glimepiride vs glibenclamide on glycemic control and macrovascular events in Japanese Type 2 diabetic patients. J Diabetes Mellitus. 2014;4:33–7.CrossRef
46.
Nakamura I, Oyama J-I, Komoda H, Shiraki A, Sakamoto Y, Taguchi I, Hiwatashi A, Komatsu A, Takeuchi M, Yamagishi S-I. Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report. Cardiovasc Diabetol. 2014;13:15.CrossRefPubMedPubMedCentral
47.
Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker K, Kiowski W, Amann F, Gruber D, Harris S. Sulfonylureas and ischaemic preconditioning. Eur Heart J. 1999;20:439–46.CrossRefPubMed
48.
Sato T, Nishida H, Miyazaki M, Nakaya H. Effects of sulfonylureas on mitochondrial ATP-sensitive K + channels in cardiac myocytes: implications for sulfonylurea controversy. Diabetes Metab Res Rev. 2006;22(5):341–7.CrossRefPubMed
49.
Cheng C-L, Lee C-H, Chen P-S, Li Y-H, Lin S-J, Yang Y-HK. Validation of acute myocardial infarction cases in the national health insurance research database in Taiwan. J Epidemiol. 2014;24(6):500.CrossRefPubMedPubMedCentral
50.
Hsieh C-Y, Chen C-H, Li C-Y, Lai M-L. Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J Formos Med Assoc. 2015;114(3):254–9.CrossRefPubMed
51.
Metadata
Title
Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study
Authors
Huang-Tz Ou
Kai-Cheng Chang
Chung-Yi Li
Jin-Shang Wu
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2016
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-016-0350-4

Other articles of this Issue 1/2016

Cardiovascular Diabetology 1/2016 Go to the issue

Original investigation

Mortality and causes of death in a national sample of type 2 diabetic patients in Korea from 2002 to 2013

Original investigation

Use of imaging and clinical data to screen for cardiovascular disease in asymptomatic diabetics

Original investigation

Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study

Original investigation

Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

Original investigation

Determinants of growth differentiation factor 15 in patients with stable and acute coronary artery disease. A prospective observational study

Original investigation

Metformin improves the angiogenic potential of human CD34+ cells co-incident with downregulating CXCL10 and TIMP1 gene expression and increasing VEGFA under hyperglycemia and hypoxia within a therapeutic window for myocardial infarction
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits